Page 7 - Glycomimetics Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesLeo vartorellaHarout semerjianExchange commissionCompany annual report on formGlycomimetics incChief executive officerSouthern mediterraneanMiddle eastAcute myeloid leukemiaBiohealth capitalAnnual report

GlycoMimetics (GLYC) Reports Positive Initial Safety and Pharmacokinetic Results from Phase 1a Study of GMI-1687

GlycoMimetics (GLYC) Reports Positive Initial Safety and Pharmacokinetic Results from Phase 1a Study of GMI-1687
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Harout semerjianGlycomimetics incChief executive officer

Comparing GlycoMimetics (NASDAQ:GLYC) & NLS Pharmaceutics (NASDAQ:NLSP)

GlycoMimetics (NASDAQ:GLYC – Get Free Report) and NLS Pharmaceutics (NASDAQ:NLSP – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Earnings & Valuation This table compares GlycoMimetics and NLS […]

United statesGlycomimetics incNational cancer instituteApollomics hong kongGet free reportGiven glycomimeticHong kongGlycomimetics dailyNasdaq glycStock comparisonStock analysis

GlycoMimetics (NASDAQ:GLYC) Lifted to Hold at StockNews com

StockNews.com upgraded shares of GlycoMimetics (NASDAQ:GLYC – Free Report) from a sell rating to a hold rating in a research report released on Thursday morning. Separately, Capital One Financial assumed coverage on GlycoMimetics in a research report on Friday, December 22nd. They set an overweight rating and a $12.00 target price for the company. Check […]

United statesAcuta capital partnersTopco ltdCharles schwab investment management incTower research capitalGlycomimetics incGlycomimetics company profileFree reportCapital one financialMimetics trading downGet free reportSchwab investment managementResearch capitalStreet groupCapital partnersGlycomimetics daily

Analyzing NLS Pharmaceutics (NASDAQ:NLSP) and GlycoMimetics (NASDAQ:GLYC)

NLS Pharmaceutics (NASDAQ:NLSP – Get Free Report) and GlycoMimetics (NASDAQ:GLYC – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Earnings and Valuation This table compares NLS Pharmaceutics and […]

United statesNational cancer instituteApollomics hong kongGlycomimetics incGet free reportGiven glycomimeticHong kongNls pharmaceuticsNasdaq nlspStock comparisonStock analysis